Table 3.
Toxicity according to performance status and treatment
| Toxicity | ECOG 2 group | ECOG 0–1 group | pb | ||||
|---|---|---|---|---|---|---|---|
| EP arm (n = 31) |
PC arm (n = 40) |
pa | EP arm (n = 64) |
PC arm (n = 56) |
pa | ||
| Hematological | 0.663 | 0.725 | 0.854 | ||||
| Grade 3/4 | 10 (32.3%) | 11 (27.5%) | 19 (29.7%) | 15 (26.8%) | |||
| Grade 1/2 | 21 (67.7%) | 29 (72.5%) | 45 (70.3%) | 41 (73.2%) | |||
| Esophagitis | 0.078 | 0.017 | 0.230 | ||||
| Grade 3 | 8 (25.8%) | 4 (10.0%) | 11 (17.2%) | 2 (3.6%) | |||
| < Grade 3 | 23 (74.2%) | 36 (90.0%) | 53 (82.8%) | 54 (96.4%) | |||
| Radiation pneumonitis | 0.014 | 0.066 | 0.428 | ||||
| ≥ Grade 3 | 0 (0.0%) | 7 (17.5%) | 7 (10.9%) | 1 (1.8%) | |||
| < Grade 3 | 31 (100.0%) | 33 (82.5%) | 57 (89.1%) | 55 (98.2%) | |||
| Gastrointestinal toxicity | 0.327 | 0.285 | 0.950 | ||||
| ≥ Grade 3 | 3 (9.7%) | 8 (20.0%) | 8 (12.5%) | 11 (19.6%) | |||
| < Grade 3 | 28 (90.3%) | 32 (80.0%) | 56 (87.5%) | 45 (80.4%) | |||
| Dermatological toxicity | 0.598 | 0.296 | |||||
| ≥ Grade 3 | 0 (0.0%) | 0 (0.0%) | 1 (1.6%) | 2 (3.6%) | |||
| < Grade 3 | 31 (100.0%) | 40 (100.0%) | 63 (98.4%) | 54 (96.4%) | |||
Abbreviations: EP etoposide/cisplatin, PC paclitaxel/carboplatin, ECOG Eastern Cooperative Oncology Group
ap value for testing the null hypothesis of no difference between patients receiving EP and PC chemotherapy
bp value for testing the null hypothesis of no difference between ECOG 2 group and ECOG 0–1 group